In vitroapproach for identification of the most effective agents for antimicrobial lock therapy in the treatment of intravascular catheter-related infections caused by staphylococcus aureus
Hogan, S. ; Zapotoczna, M. ; Stevens, N. T. ; Humphreys, H. ; O'Gara, J. P. ; O'Neill, E.
Hogan, S.
Zapotoczna, M.
Stevens, N. T.
Humphreys, H.
O'Gara, J. P.
O'Neill, E.
Repository DOI
Publication Date
2016-02-29
Type
Article
Downloads
Citation
Hogan, S. Zapotoczna, M.; Stevens, N. T.; Humphreys, H.; O'Gara, J. P.; O'Neill, E. (2016). In vitroapproach for identification of the most effective agents for antimicrobial lock therapy in the treatment of intravascular catheter-related infections caused by staphylococcus aureus. Antimicrobial Agents and Chemotherapy 60 (5), 2923-2931
Abstract
Infection of intravascular catheters by Staphylococcus aureus is a significant risk factor within the health care setting. To treat these infections and attempt salvage of an intravascular catheter, antimicrobial lock solutions ( ALSs) are being increasingly used. However, the most effective ALSs against these biofilm-mediated infections have yet to be determined, and clinical practice varies greatly. The purpose of this study was to evaluate and compare the efficacies of antibiotics and antiseptics in current clinical use against biofilms produced by reference and clinical isolates of S. aureus. Static and flow biofilm assays were developed using newly described in vivo-relevant conditions to examine the effect of each agent on S. aureus within the biofilm matrix. The antibiotics daptomycin, tigecycline, and rifampin and the antiseptics ethanol and Taurolock inactivated established S. aureus biofilms, while other commonly used antistaphylococcal antibiotics and antiseptic agents were less effective. These findings were confirmed by live/dead staining of S. aureus biofilms formed and treated within a flow cell model. The results from this study demonstrate the most effective clinically used agents and their concentrations which should be used within an ALS to treat S. aureus-mediated intravascular catheter-related infections.
Funder
Publisher
American Society for Microbiology
Publisher DOI
10.1128/aac.02885-15
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland